On June 17, 2022, the launch event of Zi Sheng ® which was sponsored by Shanghai Yizhong Pharma Co., Ltd. (hereafter referred to as Shanghai Yizhong, 688091.SH) and Qingdao Baheal Medical INC. (hereafter referred to as Baheal Medical, 301015.SZ) was propitiously conducted. Topics discussed included those that will open a new era for paclitaxel and a highly-effective targeted chemotherapy.

This was drawn as the starting point to jointly promote the transformation and application of successful scientific research projects, with the goal of establishing a medical and health demonstration area to drive world-class research and innovation.

On February 12, 2022, Shanghai Yizhong and Baheal Medical signed a cooperative agreement in Qingdao.

CH Biomedical, an innovative R&D company incubated by the investment section of Baheal Pharmaceutical Group, announced that its new generation of fully magnetically levitated artificial heart was officially approved for marketing.

Qingdao Baheal Medical Inc. and Astellas Pharma China Inc. reached a deeper cooperation agreement on the promotion and operation of Astellas' drugs Betmiga® (mirabellum extended-release tablets), Vesicare® (solifenacin succinate tablets) and Harnal® (tamsulosin hydrochloride extended-release capsules) in mainland China.